Fundraising Foxre.Mind Capital — 2021 Investments
5 investments dated 2021 · listed companies and verified rows first · show all
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier Partners+12 more
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
David Olson(Founder)David Olson Nick Haft(Founder)Nick Haft(Founder)
Co-investorsArtis VenturesBailey Venture PartnersCasa Verde CapitalDolby Family VenturesGaingelsIaso Ventures+9 more
__Twitter.png)
Active seed-stage healthcare company
Eugene, US
Nicholas Allen(Chief Executive Officer)Phillip Scripa(Chief Financial Officer and Secretary)William Shortt(Chief Operating Officer)Jan Hardorp(Director)in
Co-investorsBIP VenturesJLSPalo Santo VCWPSS Investments
Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline.
BiotechDeep TechMedical DevicesCampbell, US
Thomas James Oxley(Executive Officer, Director)Nicholas Opie(Founder)inThomas Oxley(Founder)inTom Oxley(Founder)
BoardRahul Sharma(Director)Alex Morgan(Director)in
Co-investorsAlumni VenturesARCH Venture PartnersForepont Capital PartnersID8 InvestmentsIn-Q-TelK2 Global+15 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.